| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Alkermes plc (NASDAQ: ALKS)
ALKS Technical Analysis
5
| As on 9th Jun 2023 ALKS SHARE Price closed @ 31.13 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 25.81 & Strong Buy for SHORT-TERM with Stoploss of 24.23 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALKSSHARE Price
| Open | 31.35 | Change | Price | % |
| High | 31.54 | 1 Day | -0.41 | -1.30 |
| Low | 31.03 | 1 Week | 2.20 | 7.60 |
| Close | 31.13 | 1 Month | 2.79 | 9.84 |
| Volume | 915400 | 1 Year | 7.57 | 32.13 |
| 52 Week High 31.87 | 52 Week Low 21.94 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ALKS Daily Charts |
ALKS Intraday Charts |
Whats New @ Bazaartrend |
ALKS Free Analysis |
|
|
ALKS Important Levels Intraday
| RESISTANCE | 32.11 |
| RESISTANCE | 31.80 |
| RESISTANCE | 31.60 |
| RESISTANCE | 31.41 |
| SUPPORT | 30.85 |
| SUPPORT | 30.66 |
| SUPPORT | 30.46 |
| SUPPORT | 30.15 |
ALKS Forecast April 2024
| 4th UP Forecast | 38.99 |
| 3rd UP Forecast | 36.47 |
| 2nd UP Forecast | 34.91 |
| 1st UP Forecast | 33.35 |
| 1st DOWN Forecast | 28.91 |
| 2nd DOWN Forecast | 27.35 |
| 3rd DOWN Forecast | 25.79 |
| 4th DOWN Forecast | 23.27 |
ALKS Weekly Forecast
| 4th UP Forecast | 33.75 |
| 3rd UP Forecast | 32.91 |
| 2nd UP Forecast | 32.39 |
| 1st UP Forecast | 31.87 |
| 1st DOWN Forecast | 30.39 |
| 2nd DOWN Forecast | 29.87 |
| 3rd DOWN Forecast | 29.35 |
| 4th DOWN Forecast | 28.51 |
ALKS Forecast2024
| 4th UP Forecast | 52.4 |
| 3rd UP Forecast | 45.58 |
| 2nd UP Forecast | 41.36 |
| 1st UP Forecast | 37.15 |
| 1st DOWN Forecast | 25.11 |
| 2nd DOWN Forecast | 20.9 |
| 3rd DOWN Forecast | 16.68 |
| 4th DOWN Forecast | 9.86 |
Alkermes plc ( NASDAQ USA Symbol : ALKS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALKS Business Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Address: Connaught House, Dublin, Ireland, 4
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service